Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advanced<em>EGFR</em>mutation-positive lung adenocarcinoma
Background and purpose: For patients with advanced lung adenocarcinoma harboring an activating EGFR gene mutation, the current standard of care is EGFR-TKI alone. This study aimed to compare efficacy and safety of gefitinib plus chemotherapy with gefitinib or chemotherapy alone for treating advanced...
Furkejuvvon:
| Váldodahkkit: | , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Editorial Office of China Oncology
2015-12-01
|
| Ráidu: | Zhongguo aizheng zazhi |
| Fáttát: | |
| Liŋkkat: | http://www.china-oncology.com/thesisDetails#10.3969/j.issn.1007-3969.2015.10.001 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|